

**EFFECTIVE DATE:** 12|01|2019

**POLICY LAST UPDATED:** 08|06|2019

## OVERVIEW

Polivy™ (polatuzumab vedotin-piiq) is indicated, in combination with bendamustine and a rituximab product, for the treatment of adult patients with relapsed refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies

This policy is applicable to BlueCHiP for Medicare products only. For Commercial Products, see related policy section.

## MEDICAL CRITERIA

### Initial Evaluation

Polivy™ (polatuzumab vedotin-piiq) will be approved when ONE of the following are met:

1. There is documentation provided with the request (e.g. treatment start date, length of treatment, patient's clinical benefit from therapy) indicating that the patient is currently being treated with the requested agent

OR

2. ALL of the following:

- a. ONE of the following:

- i. The patient has an FDA labeled indication for the requested agent AND ALL of the following:

1. ONE of the following:

- a. The requested indication does NOT require genetic/specific diagnostic testing (e.g., ALK, EGFR, HER2, KRAS) in FDA labeling

OR

- b. The requested indication requires genetic/specific diagnostic testing in the FDA labeling AND ONE of the following:

- i. BOTH of the following:

1. Genetic/diagnostic testing has been performed

AND

2. The results of the genetic/diagnostic testing indicate therapy with the requested agent is appropriate

OR

- ii. The requested indication does not require genetic/specific diagnostic testing in NCCN with level of evidence 1 or 2a

AND

2. ONE of the following:

- a. The requested agent is FDA labeled as a first-line agent for the requested indication

OR

- b. The patient has used the appropriate number and type(s) of prerequisite agent(s) listed in the FDA labeling for the requested indication

**OR**

- c. The patient has used the appropriate number and type(s) of prerequisite agent(s) supported by NCCN 1 or 2A recommended use for the requested indication

**OR**

- d. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ALL of the required prerequisite agent(s) listed in the FDA labeling for the requested indication

**AND**

- 3. ONE of the following:

- a. The requested agent is approved for use as monotherapy in the FDA labeling for the requested indication

**OR**

- b. The requested agent will be used with all agent(s) and/or treatments (e.g., radiation) listed for concomitant use in the FDA labeling for the requested indication

**OR**

- c. The requested agent will be used with all agent(s) and/or treatments supported in NCCN 1 or 2a recommended use for the requested indication

**AND**

- 4. ONE of the following:

- a. The FDA label does NOT include a performance status requirement

**OR**

- b. The patient meets the performance status requirement in the FDA labeling

**AND**

- 5. If the client has preferred agents\* (\*preferred agents determined by client) ONE of the following:

- a. The requested agent is a preferred agent

**OR**

- b. The requested agent is a non-preferred agent (Herceptin Hylecta, Infugem) AND ONE of the following:

- i. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ALL preferred agent(s) for the requested indication and would not be expected to occur with the requested agent

**OR**

- ii. The prescriber has submitted documentation in support of the non-preferred agent over the preferred agent(s) for the requested indication (convenience is not a qualified reason)

**OR**

- ii. BOTH of the following:

- 1. The use of the target agent is for an indication that is supported by compendia. (NCCN Compendium™ [level of evidence 1, 2A], AHFS, DrugDex [FDA approved Class I or Class IIa]), or the prescriber has submitted additional documentation (the use is supported by clinical research in 2 or more peer reviewed medical journals) supporting the requested therapeutic use (approval by the Clinical Review Pharmacist required).

**AND**

2. If the client has preferred agents\* (\*preferred agents determined by client) ONE of the following:

a. The requested agent is a preferred agent

**OR**

b. The requested agent is a non-preferred agent (Herceptin Hylecta, Infugem) AND ONE of the following:

i. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ALL preferred agent(s) for the requested indication and would not be expected to occur with the requested agent

**OR**

ii. The prescriber has submitted documentation in support of the non-preferred agent over the preferred agent(s) for the requested indication (convenience is not a qualified reason)

**AND**

b. The patient does NOT have any FDA labeled contraindications to the requested agent

**AND**

c. The requested dose is within FDA labeling or dose and duration is supported by compendia. (NCCN Compendium™ [level of evidence 1, 2A], AHFS, DrugDex [FDA approved Class I or Class IIa]), or the prescriber has submitted additional documentation (the dose is supported by clinical research in 2 or more peer reviewed medical journals) supporting the requested therapeutic dose (approval by the Clinical Review Pharmacist required)

**Length of Approval:** 12 months or for duration of treatment as supported in FDA labeling or NCCN compendia, whichever is shorter.

**PRIOR AUTHORIZATION**

Prior authorization is required for BlueCHiP for Medicare.

**POLICY STATEMENT**

**BlueCHiP for Medicare**

Polivy™ (polatuzumab vedotin-piiq) is medically necessary when the criteria above have been met.

**COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable physician administered drug benefits/coverage.

**BACKGROUND**

**Clinical Rationale**

For the purposes of the Injectable Oncology Agents criteria, indications deemed appropriate are those approved in FDA labeling and/or supported by NCCN Drugs & Biologics compendia with a category 1 or 2A recommendation.

**CODING**

**BlueCHiP for Medicare**

**J9309** Injection, polatuzumab vedotin-piiq, 1 mg (new code effective 1/1/20)

(Prior to 1/1/20, there is no specific HCPCS code. Claims dated before 1/1/20 must be filed with an unlisted code such as J3490 and the NDC number.)

**RELATED POLICIES**

Prior Authorization of Drugs

## PUBLISHED

Provider Update, October 2019

## REFERENCES

1. Polivy Prescribing Information. Genentech Inc. June 2019.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

